Lung Cancer

The PCF Young Investigator Award-Class of 2022 recipients are: 2022 Todd Boehly – PCF Young Investigator Award Vipul Bhatia, PhD Fred Hutchinson Research Center Mentors: John K. Lee, MD, PhD, Peter Nelson, MD Development of Next-Generation STEAP1 Chimeric Antigen Receptor T Cell Therapies to Combat Antigen Escape and T Cell Dysfunction Description: Cancer immunotherapies that have been highly effective in other cancer types are rarely effective in prostate cancer. New strategies to optimize immunotherapy in prostate cancer are needed. Chimeric antigen receptor (CAR) T cells are a type of personalized immunotherapy in which a patient's own T cells are engineered to recognize and target their cancer.  CAR T cells are highly effective in leukemias and lymphomas and are under development for other cancer types.   In this project, Dr. Vipul Bhatia and team are developing CAR T cells that may be more effective in prostate cancer, by targeting two p

[unable to retrieve full-text content] FDA keeps Jazz's lung cancer accelerated approval in place—for now—despite failed trial and calls for withdrawal    FiercePharma

Dahleen Glanton  |  Chicago Tribune It appears that Rush Limbaugh is dying. He announced on his radio show Monday that his lung cancer had gotten worse and is "going in the wrong direction." I have never cared for Limbaugh's kind of politics. I've always felt like the right-wing talk radio host's sole purpose was to further polarize America and push conservatives further away from a middle ground. In spite of that, I am saddened that his cancer is terminal. I would like to see his condition turn around, but he doesn't seem to think that it will. More: 'Do things that would make them proud:' Bragg paratrooper's family honors his memory at White House Gold Star event More: Rush Limbaugh says his stage 4 lung cancer has progressed 'in the wrong direction' More: In NC, pandemic points to need for cooperation on climate "It's tough to realize that the days where I do not think I'm under a death sentence are over,

Common causes of bloody semen include infection, injury, and prostate cancer treatment.   Bloody semen may not have a specific cause, and it's usually not serious if it only happens once. Check in with a doctor if you're over age 40, have other symptoms, or the blood doesn't go away. If you notice blood in your semen, you might feel pretty alarmed, but there's no need to head to the emergency room just yet. Hematospermia — the medical name for blood in your semen — usually doesn't suggest a serious health condition.  Though sometimes caused by infections, this blood often has no clear cause and will usually go away on its own within a few days or weeks, according to Dr. Francisco Gelpi-Hammerschmidt, a urologist at Memorial Hermann.  The best course of action usually involves waiting i

This investigation compared the histologic features of basal cell carcinoma (BCC) between organ transplant recipients and the general population. Development and progression of basal cell carcinoma (BCC) were more common among organ transplant recipients (OTRs) compared with the general population, and the former also had a higher rate of deep invasion, according to new study findings published in Archives of Dermatological Research . The study authors note that their data point to immunosuppression as the culprit, which echoes previous research and highlights the greater skin cancer risk these patients face. "The most frequently occurring skin cancers in OTRs are squamous cell carcinomas (SCCs), and because they are responsible for high morbidity and mortality, SCCs in OTRs have been studied extensively," the investigators wrote. "BCCs occur less frequently than SCCs and rarely metastasize, and thus BCCs in OTRs have received relatively little attention despite their

Meanwhile, Dr Mike Turner commented: "Skin cancer is on the rise in many countries and any insight into the body's ability to prevent tumour formation is valuable in the fight against this form of cancer. "These findings that eczema can protect individuals from skin cancer support theories linking allergies to cancer prevention and open up new avenues for exploration whilst providing some (small) comfort for those suffering from eczema." However, while the study may have opened up new avenues and provided an insight into eczema's link with skin cancer, there is one key caveat. The study was published in 2014; as a result, it is important to take into account the possibility that a new theory may have been released showing the opposite.

The PCF Young Investigator Award-Class of 2022 recipients are: 2022 Todd Boehly – PCF Young Investigator Award Vipul Bhatia, PhD Fred Hutchinson Research Center Mentors: John K. Lee, MD, PhD, Peter Nelson, MD Development of Next-Generation STEAP1 Chimeric Antigen Receptor T Cell Therapies to Combat Antigen Escape and T Cell Dysfunction Description: Cancer immunotherapies that have been highly effective in other cancer types are rarely effective in prostate cancer. New strategies to optimize immunotherapy in prostate cancer are needed. Chimeric antigen receptor (CAR) T cells are a type of personalized immunotherapy in which a patient's own T cells are engineered to recognize and target their cancer.  CAR T cells are highly effective in leukemias and lymphomas and are under development for other cancer types.   In this project, Dr. Vipul Bhatia and team are developing CAR T cells that may be more effective in prostate cancer, by targeting two p